Скачать с ютуб Psychedelics for Human Suffering: A New Paradigm for the 21st Century – Charles S. Grob в хорошем качестве

Psychedelics for Human Suffering: A New Paradigm for the 21st Century – Charles S. Grob

Clinical research on psychedelics has come a long way from its origins in the middle of the 20th century. One of the key figures in the current revival of psychedelic research is psychiatrist Charles S. Grob, who has, since the 1990s, conducted important research on ayahuasca and psilocybin, amongst others. On December 2023, Dr. Grob talked about the history of psychedelic research and the implications of his own research projects – both for future projects and the practice of psychiatry and medicine, in a webinar organized by the Finnish Association for Psychedelic Research (Psykedeelitutkimusyhdistys ry). The talk reviews the history, ethnobotany, pharmacology, and clinical research record of psychedelic drugs in human subjects. Prior investigations during the 1950s and 1960s are examined, as are the socio-cultural reactions that led to their termination by the early 1970s. Dr. Grob aloso gave an overview of the reemergence of psychedelic research in the modern era, with particular emphasis on recent research using a psilocybin treatment model in the treatment of human subjects with advanced-stage medical illness approaching the end of life, who are suffering from severe existential distress and demoralization. The implications of this body of investigation are addressed, with an emphasis on the necessity to safeguard optimal safety and ethical conduct. Particular attention is given to the rationale, methodology, and development of a new multi-site research project designed to explore the utility of psychedelic treatment at the end of life in the palliative care setting. Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. He previously held faculty positions at the Johns Hopkins School of Medicine and the University of California at Irvine. He has conducted approved clinical research with psychedelics since the early 1990s. From 2004-2008 he was the Principal Investigator of the first study in several decades to examine the use of a psilocybin treatment model for patients with advanced-cancer anxiety. He has also conducted research into the range of effects of MDMA, in both normal volunteers and in a selected subject population of adult autistics with severe social anxiety. And, he has conducted a series of ayahuasca research studies in Brazil. Over the last thirty years Dr. Grob has published numerous articles and chapters on psychedelics in the medical and psychiatric literatures and he is the editor of Hallucinogens: A Reader (Putnam/Tarcher, 2002), co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics (SUNY Press, 2005) and co-editor (with James Grigsby) of the recently published Handbook of Medical Hallucinogens (Guilford Press, 2021). He is a founding board member of the Heffter Research Institute. 00:00:00 Lecture 01:21:57 Q&A • • • • • The Finnish Association for Psychedelic Research (Psykedeelitutkimusyhdistys ry) is a multidisciplinary association founded in December 2016 with the goals of promoting scientific research related to psychedelics and the availability of accessible information based on such research. We encourage you to become a member – more info at http://psyty.fi/mukaan. We also accept donations, more info at https://psyty.fi/lahjoita. More on Psyty: https://psyty.fi Our social media channels:   / psyty   http://x.com/psytyfi   / psyty      / psyty